Forge Therapeutics, founded in 2015 with the goal of developing drugs that target metalloenzymes, said Wednesday it had agreed to let Basilea Pharmaceutica use its chemistry platform to develop new antibiotics.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,